Blueprint Medicines Stock Forecast

Stock Price Forecast

The 18 analysts with 12-month price forecasts for Blueprint Medicines stock had an average target of $128.87, with a low estimate of $105 and a high estimate of $138.

Price Target: $128.87 (-0.46%)

Analyst Consensus: Buy

Price Target

Target	Low	Average	Median	High
Price	$105	$128.87	n/a	$138
Change	-18.89%	-0.46%	n/a	+6.60%

Analyst Ratings

The average analyst rating for Blueprint Medicines stock from 18 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.

Recommendation Trends

No data available

Rating	Oct 2026
Strong Buy	n/a
Buy	n/a
Hold	n/a
Sell	n/a
Strong Sell	n/a
Total	n/a

Financial Forecast

Revenue This Year

735.04M

from 508.82M

44.46%

from 508.82M

Revenue Next Year

975.99M

from 735.04M

32.78%

from 735.04M

EPS This Year

-0.91

from -1.07

EPS Next Year

0.99

from -0.91

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	793.74M	180.08M	204.04M	249.38M	508.82M	735.04M	975.99M
Revenue Growth	1,093.37%	-77.31%	13.30%	22.22%	104.04%	44.46%	32.78%
EPS	5.59	-11.01	-9.35	-8.37	-1.07	-0.91	0.99
Forward PE	-	-	-	-	-	-	131.18
No. Analysts	-	-	-	-	-	23	23

Revenue Forecast

Revenue	2025	2026
High	811.7M	1.1B
Avg	735.0M	976.0M
Low	692.4M	841.8M

Revenue Growth

Revenue Growth	2025	2026
High	59.5%	45.0%
Avg	44.5%	32.8%
Low	36.1%	14.5%

EPS Forecast

EPS	2025	2026
High	1.24	3.22
Avg	-0.91	0.99
Low	-2.05	-1.92

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-